Update on new drugs and those in development for the treatment of primary biliary cholangitis

Runalia Bahar, Kimberly A. Wong, Chung H. Liu, Christopher Bowlus

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Primary biliary cholangitis (PBC) is an autoimmune inflammatory liver disease of the interlobular bile ducts that can lead to cirrhosis and liver failure. Until recently, the only effective treatment was ursodeoxycholic acid (UDCA). However, up to 40% of PBC patients have an inadequate response to UDCA and may continue to have disease progression. Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). The addition of OCA can significantly improve serum alkaline phosphatase and total bilirubin, which are strong surrogate markers of clinical outcomes in PBC. Other alternatives, including the peroxisome proliferator-activated receptor (PPAR)-? agonists fenofibrate and bezafibrate, may also improve liver biochemistries in PBC patients with an inadequate response to UDCA, but further study is needed to demonstrate their safety and long-term efficacy. Other novel agents, including those targeting the FXR pathway and PPAR-? agonists, have shown promising results and may alter the therapeutic landscape of PBC in the near future. For now, OCA remains the only approved second-line agent for PBC patients with an inadequate response to UDCA while results of long-term studies of its safety and clinical benefit are awaited.

Original languageEnglish (US)
Pages (from-to)154-163
Number of pages10
JournalGastroenterology and Hepatology
Volume14
Issue number3
StatePublished - Mar 1 2018

Fingerprint

Cholangitis
Ursodeoxycholic Acid
Pharmaceutical Preparations
Peroxisome Proliferator-Activated Receptors
Therapeutics
Bezafibrate
Fenofibrate
Safety
Liver Failure
Bile Ducts
Bilirubin
Biochemistry
Alkaline Phosphatase
Disease Progression
Liver Diseases
Fibrosis
Biomarkers
Liver
Serum
6-ethylchenodeoxycholic acid

Keywords

  • Farnesoid X receptor
  • FGF19 analog
  • Fibrate
  • Peroxisome proliferator-activated receptor agonist
  • Primary biliary cholangitis
  • Therapy

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Update on new drugs and those in development for the treatment of primary biliary cholangitis. / Bahar, Runalia; Wong, Kimberly A.; Liu, Chung H.; Bowlus, Christopher.

In: Gastroenterology and Hepatology, Vol. 14, No. 3, 01.03.2018, p. 154-163.

Research output: Contribution to journalArticle

@article{a3613984606c45e0a3696449908cc8c5,
title = "Update on new drugs and those in development for the treatment of primary biliary cholangitis",
abstract = "Primary biliary cholangitis (PBC) is an autoimmune inflammatory liver disease of the interlobular bile ducts that can lead to cirrhosis and liver failure. Until recently, the only effective treatment was ursodeoxycholic acid (UDCA). However, up to 40{\%} of PBC patients have an inadequate response to UDCA and may continue to have disease progression. Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). The addition of OCA can significantly improve serum alkaline phosphatase and total bilirubin, which are strong surrogate markers of clinical outcomes in PBC. Other alternatives, including the peroxisome proliferator-activated receptor (PPAR)-? agonists fenofibrate and bezafibrate, may also improve liver biochemistries in PBC patients with an inadequate response to UDCA, but further study is needed to demonstrate their safety and long-term efficacy. Other novel agents, including those targeting the FXR pathway and PPAR-? agonists, have shown promising results and may alter the therapeutic landscape of PBC in the near future. For now, OCA remains the only approved second-line agent for PBC patients with an inadequate response to UDCA while results of long-term studies of its safety and clinical benefit are awaited.",
keywords = "Farnesoid X receptor, FGF19 analog, Fibrate, Peroxisome proliferator-activated receptor agonist, Primary biliary cholangitis, Therapy",
author = "Runalia Bahar and Wong, {Kimberly A.} and Liu, {Chung H.} and Christopher Bowlus",
year = "2018",
month = "3",
day = "1",
language = "English (US)",
volume = "14",
pages = "154--163",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "3",

}

TY - JOUR

T1 - Update on new drugs and those in development for the treatment of primary biliary cholangitis

AU - Bahar, Runalia

AU - Wong, Kimberly A.

AU - Liu, Chung H.

AU - Bowlus, Christopher

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Primary biliary cholangitis (PBC) is an autoimmune inflammatory liver disease of the interlobular bile ducts that can lead to cirrhosis and liver failure. Until recently, the only effective treatment was ursodeoxycholic acid (UDCA). However, up to 40% of PBC patients have an inadequate response to UDCA and may continue to have disease progression. Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). The addition of OCA can significantly improve serum alkaline phosphatase and total bilirubin, which are strong surrogate markers of clinical outcomes in PBC. Other alternatives, including the peroxisome proliferator-activated receptor (PPAR)-? agonists fenofibrate and bezafibrate, may also improve liver biochemistries in PBC patients with an inadequate response to UDCA, but further study is needed to demonstrate their safety and long-term efficacy. Other novel agents, including those targeting the FXR pathway and PPAR-? agonists, have shown promising results and may alter the therapeutic landscape of PBC in the near future. For now, OCA remains the only approved second-line agent for PBC patients with an inadequate response to UDCA while results of long-term studies of its safety and clinical benefit are awaited.

AB - Primary biliary cholangitis (PBC) is an autoimmune inflammatory liver disease of the interlobular bile ducts that can lead to cirrhosis and liver failure. Until recently, the only effective treatment was ursodeoxycholic acid (UDCA). However, up to 40% of PBC patients have an inadequate response to UDCA and may continue to have disease progression. Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). The addition of OCA can significantly improve serum alkaline phosphatase and total bilirubin, which are strong surrogate markers of clinical outcomes in PBC. Other alternatives, including the peroxisome proliferator-activated receptor (PPAR)-? agonists fenofibrate and bezafibrate, may also improve liver biochemistries in PBC patients with an inadequate response to UDCA, but further study is needed to demonstrate their safety and long-term efficacy. Other novel agents, including those targeting the FXR pathway and PPAR-? agonists, have shown promising results and may alter the therapeutic landscape of PBC in the near future. For now, OCA remains the only approved second-line agent for PBC patients with an inadequate response to UDCA while results of long-term studies of its safety and clinical benefit are awaited.

KW - Farnesoid X receptor

KW - FGF19 analog

KW - Fibrate

KW - Peroxisome proliferator-activated receptor agonist

KW - Primary biliary cholangitis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85044568316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044568316&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85044568316

VL - 14

SP - 154

EP - 163

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 3

ER -